Inotec AMD Limited appoints new Vice President – America
Cambridge, UK – 15 August 2018 – Cambridge based Inotec AMD Limited is pleased to announce the appointment of Kathy Hohenberger as its new Vice President – America on 10 September 2018.
Kathy Hohenberger has over 25 years of progressive experience in the healthcare and medical device industry. She brings on board a proven track record of building business in the healthcare sector and the wound care space. Most notably, she worked for 3 years as Vice President, USA of Acelity, a global advanced wound therapeutics company, where she significantly grew the Systagenix business through to its acquisition by KCI. Prior to Acelity, Kathryn’s proven leadership was realized as she grew in responsibililty & scope at Hill-Rom company, including the executive position VP Clinical Division which focused on improving patient outcomes across the care continuum. Additionally, she also was the Director for Gentiva Home Health, national leader of home health and hospice services where her leadership was focused on providing top notch clinical services for patients in need.
Mr Kennedy, CEO of Inotec AMD said “We are pleased to announce the appointment of Kathy Hohenberger who will be starting her new role as VP, America of the company in September. We believe that her extensive experience of the wound care market will drive the growth of Inotec AMD’s NATROX® Oxygen Wound Therapy in the USA. Kathy’s appointment is a significant step forward for Inotec AMD. Along with a local US base, she enables Inotec AMD to bring its products closer to customers in the region and paves the way for penetration into the one of the fastest growing wound care markets. We plan to expand our commitment to the US market, adding more resources to our US office in the very near future”.
Ms Hohenberger commented that “I am excited to join the Inotec AMD team at this exciting time. NATROX® is a excellent product with great potential to positively impact the lives of millions of people living with debilitating chronic wounds. The industry is ripe for the introduction of clinically effective active therapy to improve the lives of millions living with these wounds.”
NATROX® is FDA approved and Inotec AMD will continue to develop a world class team as they prepare to launch NATROX® into the United States market during 2018.